FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC

被引：0

作者：

Jie Liu

Yeling Ouyang

Zijin Xia

Wenhao Mai

Hongrui Song

Fang Zhou

Lichun Shen

Kaiting Chen

Xiaochen Li

Shi-Min Zhuang

Jing Liao

机构：

[1] Guangzhou Medical University,GMU

[2] The Sixth Affiliated Hospital,GIBH Joint School of Life Sciences, The Guangdong

[3] Sun Yat-Sen University,Hong Kong

[4] The Sixth Affiliated Hospital,Macau Joint Laboratory for Cell Fate Regulation and Diseases

[5] Sun Yat-Sen University,Department of General Surgery of Otorhinolaryngology Head and Neck

[6] Guangzhou,Biomedical Innovation Center

[7] Union Hospital,Department of Anesthesiology

[8] Tongji Medical College,Institute of Anesthesia and Critical Care Medicine

[9] Huazhong University of Science and Technology,Key Laboratory of Anesthesiology and Resuscitation, Huazhong University of Science and Technology

[10] Union Hospital,Department of Immunology and Microbiology

[11] Tongji Medical College,Central Sterile Supply Department

[12] Huazhong University of Science and Technology,undefined

[13] Ministry of Education,undefined

[14] Zhongshan School of Medicine,undefined

[15] Sun Yat-Sen University,undefined

[16] The First Affiliated Hospital,undefined

[17] Sun Yat-Sen University,undefined

来源：

Cellular Oncology | 2024年 / 47卷

关键词：

Head and neck squamous cell carcinoma; PD-1; Immune checkpoint blockade; Immunotherapy resistance; FAP; Cancer-associated fibroblasts;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：623 / 638

页数：15

共 457 条

[1] Xin Yu J(2020)Trends in clinical development for PD-1/PD-L1 inhibitors Nat. Rev. Drug. Discov. 19 163-164
[2] Hodge JP(2022)Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities Nat. Rev. Drug Discov. 21 529-540
[3] Oliva C(2022)Hallmarks of response, resistance, and toxicity to immune checkpoint blockade Cell 185 576-1618
[4] Neftelinov ST(2019)Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1 JAMA Oncol. 5 1614-537
[5] Hubbard-Lucey VM(2019)Human germ cell tumours from a developmental perspective Nat. Rev. Cancer 19 522-224
[6] Tang J(2021)Intratumoral heterogeneity in cancer progression and response to immunotherapy Nat. Med. 27 212-683
[7] Kim TK(2020)Head and neck squamous cell carcinoma Nat. Rev. Dis. Primers. 6 92-72
[8] Vandsemb EN(2019)The changing therapeutic landscape of head and neck cancer Nat. Rev. Clin. Oncol. 16 669-1928
[9] Herbst RS(2020)Head and Neck Cancer N. Engl. J. Med. 382 60-188
[10] Chen L(2019)Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Lancet. 394 1915-115